Beam Therapeutics Inc at Jefferies London Healthcare Conference Transcript
All right. Good morning, everyone. Welcome to the 2022 Jefferies London Global Healthcare Conference. I'm Michael Yee, senior biotechnology analyst at Jefferies. I'm really happy to kick off the first day of the conference, first Monday morning session, with the CEO of Beam Therapeutics, John Evans. It's great to have you up here with us in-person and to have a great discussion about all the progress at Beam.
Great to be here, Mike. Thanks.
Questions & Answers
Absolutely. Well, there's been some recent developments, which we're happy to get into. But maybe just from a high-level perspective, just to start off, obviously, company went public as a preclinical company, has advanced on its timelines to file an IND, get progress for single base pair gene editing. But why don't you just tell us about the technology very briefly as you are now in the clinic, and tell us about what we should be excited about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
